Now, keep up to date
with daily feeds of newly posted stories
about America's Seniors...click on the box
to the left
Researchers Tie Parkinson’s Drugs to Impulse
Control Problems
Newswise, April 15, 2011 — ROCHESTER, Minn.
— Mayo Clinic researchers found that
dopamine agonists used in treating
Parkinson’s disease result in impulse
control disorders in as many as 22 percent
of patients.
Mayo Clinic first reported on this topic in
2005. The follow-up study was published
online in the February 2011 issue of
Parkinsonism and Related Disorders.
Dopamine agonists, a class of drugs that
include pramipexole (Mirapex) and ropinirole
(Requip), are commonly used to treat
Parkinson’s disease. The drugs stimulate the
brain’s limbic circuits, which are thought
to be pathways for emotional, reward and
hedonistic behaviors. The medications have
been linked to such impulse control
disorders as pathological gambling and
hypersexuality and to compulsive behaviors
such as binge eating, spending, computer use
or “hobbying.”
Researchers reviewed Parkinson’s disease
patients’ records over a recent two-year
period, says Anhar Hassan, M.B., B.Ch., a
neurology fellow at Mayo Clinic and lead
investigator on the study.
“During this time, movement disorder
physicians at Mayo Clinic were keenly aware
that impulse control disorders could occur
with these dopamine agonist drugs. If they
encountered a patient who was taking this
drug, they asked them or an accompanying
family member whether or not they had
noticed any new type of behavior. What we
found was that in as many as 22 percent of
patients during that two-year period had a
new onset impulse control disorder,” she
says.
The study found that the higher the dose,
the greater the likelihood of an impulse
control behavior. “One in four patients who
were on a medium therapeutic dose of the
medication had an impulse control disorder,”
Dr. Hassan says. “For patients who were
taking a higher range of the medication,
about one in three developed an impulse
control disorder.”
Patients taking dopamine agonists should be
aware of potential behavioral changes so
they can be caught early, before they or
their families are harmed, Dr. Hassan says.
Once a new behavior is identified, reducing
or stopping the medication usually resolves
the problem over a few days to a month, she
says.
... ..
...
...